High-Throughput Analysis Identifying Drugs That Regulate Apolipoprotein A-I Synthesis.

Area of Science:

• Biochemistry
• Pharmacology
• Cardiovascular Research

Background:

• Apolipoprotein A-I (apo A-I) is the main antiatherogenic component of high-density lipoprotein (HDL).
• Despite ongoing debate on the clinical benefits of elevating HDL, research continues for drugs that safely increase HDL and apo A-I.
• Identifying novel compounds that enhance hepatic apo A-I production is crucial for developing new therapies.

Purpose of the Study:

• To screen drug libraries for novel compounds capable of increasing hepatic apo A-I production.
• To identify potential therapeutic agents for modulating apo A-I levels.

Main Methods:

• Screening of the NIH Clinical Collection (NCC) and NCC2 libraries, comprising 727 compounds.
• Treatment of hepatoma-derived cells (HepG2) and primary hepatocytes with compounds.
• Measurement of apo A-I levels using enzyme immunoassay and confirmation by Western blot analysis.

Main Results:

• Fifteen compounds significantly increased hepatic apo A-I production by 35%-54% at a concentration of 50 μM.
• Nine compounds decreased apo A-I concentrations by 25%-52%.

Conclusions:

• The study identified several compounds that modulate hepatic apo A-I production.
• Further clinical investigation is warranted to assess the efficacy of these compounds in humans.